In PCa patients, lower testosterone levels are the intended treatment effects of hormone therapy (i.e., androgen depravation therapy; ADT), such as Gonadotropin receptor hormone (GnRH) agonists and antagonists, to slow down growth of prostate cancer cells. The gene discussed is GNRH1; the disease is posterior cortical atrophy.